Alumis Inc. has reported first-quarter 2026 results alongside past Phase 3 data showing strong efficacy for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis, while revenue...
Source LinkAlumis Inc. has reported first-quarter 2026 results alongside past Phase 3 data showing strong efficacy for its oral TYK2 inhibitor envudeucitinib in moderate-to-severe plaque psoriasis, while revenue...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.